Although knowledge of cancer biology in the laboratory has increased exponentially in recent years, progress in cancer treatment in the clinic has been more gradual. To accelerate progress in the clinic, a larger group of exceptional clinician-investigators is needed to perform patient-oriented, hypothesis-driven therapeutic translational research. The MD Anderson (MDACC) K12 Paul Calabresi Program in Clinical Oncology has taken advantage of an extraordinary environment for clinical and translational research to help to fill this need. MDACC brings together 1,685 faculty and 40,000 new patients each year with a well-developed infrastructure for clinical and laboratory research and novel ideas that are supported by 188 NCI grants. For seven decades, MDACC investigators have made important contributions to clinical cancer research. Since the inception of the MDACC K12 Program in 2000, 23 junior-faculty investigators have been trained in patient-based translational research with the program's support. Currently, four faculty scholars are being trained in this program. All 18 of our graduates have become highly-productive clinician-scientists with 17 of 18 in full-time research. Four scholars have earned an M.S. or Ph.D. and three are pursuing a degree. Collectively, Calabresi Scholars have authored 397 peer-reviewed publications while participating in the program and 967 following graduation with impact factor >5 in 40.6% and >10 in 10.9%. They have competed successfully for $32.4M in grants and contracts. Over the next 5 years, faculty supported by this award will conduct hypothesis-driven clinical trials and will have the opportunity to earn an M.S. or Ph.D. in a newly-chartered program in Clinical and Translational Science. They will participate in a new monthly Master Class and a new annual Calabresi Symposium. Their Individualized Training Plans will include didactic classes, clinical trials, publications, grant applications, and long-range planning. Each Calabresi Scholar is guided by a clinical mentor and a translational mentor chosen from 36 experts in clinical, laboratory, and translational research. Particular emphasis will be placed on rigorous evaluation and recruitment of minority scholars. Two new minority scholars have already been recruited. Our overall goal is to identify and develop careers of leaders who are needed to move an increasing number of new drugs and strategies from the laboratory to the clinic and to bring insights, images, data and tissue from the clinic to the laboratory, accelerating the development of more effective, less toxic personalized therapy. Funds are requested to include five junior faculty not only from MDACC, but also from the Baylor College of Medicine and UT Health in Houston.

Public Health Relevance

Our understanding of cancer at the level of molecules, cells and tissues has increased exponentially over the last three decades, while the number of clinician-investigators needed to translate this knowledge through hypothesis-driven clinical trials has actually decreased. If we are to accelerate the development of more effective, less toxic targeted therapy and personalized care, we must train and sustain the careers of exceptional young clinician-investigators who can develop long-term programs of clinical and translational research with strategically-chosen series of innovative clinical trials with relevant correlative studies. The MD Anderson Paul Calabresi K12 Program has the track record, deep commitment, mentors, patients, infrastructure and facilities to attract and to develop the careers of young clinician-investigators who will lead the clinical and translational development of oncology over the next decades.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Physician Scientist Award (Program) (PSA) (K12)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Damico, Mark W
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
United States
Zip Code
Rosenberg, Abby R; Bradford, Miranda C; McCauley, Elizabeth et al. (2018) Promoting resilience in adolescents and young adults with cancer: Results from the PRISM randomized controlled trial. Cancer 124:3909-3917
Sahin, Ismet; Zhang, Yu; McAllister, Florencia (2018) Tumor Spheres Quantification with Smoothed Euclidean Distance Transform. J Mol Imaging Dyn 8:
Bannon, Sarah A; Montiel, Maria F; Goldstein, Jennifer B et al. (2018) High Prevalence of Hereditary Cancer Syndromes and Outcomes in Adults with Early-Onset Pancreatic Cancer. Cancer Prev Res (Phila) 11:679-686
MD Anderson Head and Neck Cancer Symptom Working Group; Kamal, Mona; Rosenthal, David I et al. (2018) Patient reported dry mouth: Instrument comparison and model performance for correlation with quality of life in head and neck cancer survivors. Radiother Oncol 126:75-80
Zhang, Hua; Sturgis, Erich; Zhu, Lijun et al. (2018) The Modifying Effect of a Functional Variant at the miRNA Binding Site in E2F1 Gene on Recurrence of Oropharyngeal Cancer Patients with Definitive Radiotherapy. Transl Oncol 11:633-638
Joint Head and Neck Radiotherapy-MRI Development Cooperative (2018) Dynamic contrast-enhanced magnetic resonance imaging for head and neck cancers. Sci Data 5:180008
Roland, Christina L; Bednarski, Brian K; Watson, Kelsey et al. (2018) Identification of preoperative factors associated with outcomes following surgical management of intra-abdominal recurrent or metastatic GIST following neoadjuvant tyrosine kinase inhibitor therapy. J Surg Oncol 117:879-885
Keung, Emily Z; Chiang, Yi-Ju; Voss, Rachel K et al. (2018) Defining the incidence and clinical significance of lymph node metastasis in soft tissue sarcoma. Eur J Surg Oncol 44:170-177
Jalloul, Randa J; Nick, Alpa M; Munsell, Mark F et al. (2018) The influence of surgeon volume on outcomes after pelvic exenteration for a gynecologic cancer. J Gynecol Oncol 29:e68
Barcenas, Carlos H; Shafaee, Maryam N; Sinha, Arup K et al. (2018) Genetic Counseling Referral Rates in Long-Term Survivors of Triple-Negative Breast Cancer. J Natl Compr Canc Netw 16:518-524

Showing the most recent 10 out of 210 publications